nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-42DE9A1E·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Observational cohort study

Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer's Disease.

Lin et al.Lin, Beric, Wisch et al.·2026·medRxiv : the preprint server for health sciences·10.64898/2026.03.31.26349851 ↗

Primary claim

Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset.

Tentative · observational carrier comparisons and threshold-based chronology do not fully identify mutation-driven presymptomatic change
In brief

A meaningful ADAD proteomic resource maps biomarker chronology and benchmarks multiplex assays, but predictive superiority is not sustained in clinical converters.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Increasing evidence suggests that accurate prediction of Alzheimer's disease (AD) symptom onset requires more than amyloid- and tau-centric biomarkers such as cerebrospinal fluid (CSF) Aβ42/40, total tau and p-tau181 and plasma p-tau217. Autosomal dominant AD (ADAD), caused by pathogenic PSEN1, PSEN2 and APP mutations with predictable age at symptom onset, presents a unique opportunity to characterize the chronological changes in proteins beyond amyloid and tau and clarify them as early biomarkers of disease onset or as biomarkers related to disease staging and progression monitoring.

METHODS: We measured 972 CSF samples corresponding to 484 participants of the Dominantly Inherited Alzheimer Disease Network (DIAN) using the NULISASeq 120 CNS Disease Panel. We first benchmarked the technology against gold-standard measurements followed by the identification of proteins that were differentially abundant in relation to mutation status and symptomatology. Next, we determined the chronological emergence of protein changes in relation to the estimated years to onset (EYO). Finally, we assessed whether specific protein measures improved the prediction of EYO in the ADAD.

FINDINGS: NULISA measurements were comparable to those previously published. We demonstrated that known early alterations in CSF amyloid and tau were followed by inflammatory and neurodegenerative responses suggesting that clinical manifestation of AD happens before the inflammatory processes is fully developed. Finally, we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values.

INTERPRETATION: Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset. Improved performance of multi-protein composite to predict EYO compared to single biomarker values highlights the added value of multiplex proteomic signatures for biomarker panel development.

Key Claims

Primary finding · Tentative

Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

observational carrier comparisons and threshold-based chronology do not fully identify mutation-driven presymptomatic change

Abstract, Interpretation
Quote verified
Secondary · Supported

known early alterations in CSF amyloid and tau were followed by inflammatory and neurodegenerative responses

EYO-based ordering supports the direction, but selected abnormality thresholds could shift individual timings

Abstract, Findings; Results, chronological changes
Quote verified
Secondary · Tentative

we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values.

superiority appears in the main test set but not in the held-out clinical converters

Abstract, Findings; Results, multiprotein models
Quote verified
Secondary · Tentative

These results suggest that mutation in these three genes drive changes that are similar regardless of the affected ADAD gene.

small gene subgroups and weak or negative effect-size correlations do not establish shared profiles

Results, gene-stratified comparison; Figure 1D
Quote verified
Secondary · Supported

Overall, we showed that NULISA measurements strongly correlate to the established immunoassay and IP-MS methods in the DIAN study

most analytes show strong cross-platform correlations, although SNAP25 is only moderately correlated

Results, benchmarking section; Figure 1A
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Large rare-disease proteomic resource

The study analyses 972 CSF samples from 484 DIAN participants, combining cross-sectional and repeated observations across the ADAD continuum.

↳ Methods, Study Participants; Table 1

#methodological rigour

Orthogonal assay benchmarking and drift handling

NULISA measurements are compared with Lumipulse, IP-MS, SMC, and other immunoassays, and suspected Aβ freeze/thaw drift is explicitly investigated and handled in the chronology analysis.

↳ Methods, Protein Measurements, Benchmarking, and Chronological Changes; Results, Figure 1A

#positioning

Substantive engagement with prior findings

The Discussion distinguishes replications from non-replications and offers platform or sample-selection explanations for discordant SNAP25, NPTX, and YWHAZ findings.

↳ Discussion, replication and non-replication paragraphs

Limitations

#reporting

Converter results undercut predictive superiority

In 24 clinical converters, the multi-protein model’s MAE was 7.88, numerically worse than p-tau217, p-tau181, PiB PET, and age alone. This qualification is not carried into the abstract or the Discussion’s robust-superiority language.

↳ Results, converter paragraph; Abstract, Interpretation; Discussion, prediction paragraph

#methodological rigour

Chronology depends on selected thresholds

The temporal sequence depends on NC-derived 90th or 10th percentiles chosen for group separation and a 50% abnormality probability threshold, without reported sensitivity analyses around those choices.

↳ Methods, Chronological Changes of Protein Abundance

#methodological rigour

Cross-gene similarity lacks statistical support

The claim of shared dynamics across genes is difficult to reconcile with effect-size correlations of −0.09 for PSEN2 and −0.22 for APP, alongside an unexplained negative PSEN1 correlation.

↳ Results, gene-stratified comparison; Figure 1D

Does this match your read? Add your assessment ↓

Nabu Commentary

The study’s contribution rests on the scale of the DIAN CSF resource, broad assay benchmarking, and integration of chronology with EYO modelling. Methodological Rigour is moderated by threshold-dependent chronology, unquantified exclusions, and unmodelled family dependence despite otherwise competent mixed modelling and internal validation. The principal interpretive problem is that the converter analysis does not reproduce the main test set’s multi-protein advantage, yet the Discussion describes robust superiority. The paper therefore functions most convincingly as a descriptive biomarker resource and platform benchmark rather than a validated prediction tool.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.3±0.1

Contribution
3.7

The study combines multiplex CSF profiling, assay benchmarking, temporal ordering, and EYO modelling in a large rare-disease cohort. It meaningfully extends prior ADAD proteomics, although much of the biological ordering confirms existing biomarker patterns.

Introduction; Results, Figures 1–2; Discussion

Early alterations in tau and amyloid were followed by inflammatory and neurodegenerative responses.

Methodological Rigour
3.2

The design includes orthogonal assay benchmarking, mixed models for repeated measurements, training-set feature selection, and held-out testing. Confidence is reduced by data-driven abnormality thresholds, unquantified QC exclusions, family dependence, and the converter analysis’s failure to confirm multi-protein superiority.

Methods, Quality Control, Chronological Changes, and Improvement of EYO Prediction; Results, Supplementary Figure 5

Although the multi-protein model showed numerically higher MAE than single protein models in converters

Reporting
3.3

The benchmark-to-chronology-to-prediction sequence is readily followable. The abstract and Discussion nevertheless generalise multi-protein superiority beyond the main test set despite contrary numerical results in converters.

Abstract, Findings and Interpretation; Results, converter paragraph; Discussion, prediction paragraph

robustly predicted time-to-symptom onset outperforming traditional single-marker approaches and amyloid imaging

Positioning
2.8

The paper engages relevant ADAD and sporadic-AD literature and reports several non-replications. Its limitations treatment is incomplete because the acknowledged low-powered converter result is followed by an unqualified statement of robust predictive superiority.

Discussion, non-replication, prediction, and limitations paragraphs

confirming the limited statistical power in this sub-cohort

Lower confidence on Methodological Rigour, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values: "The multi-protein model achieved an MAE of 7.88 (RMSE=9.11), comparable to single-biomarker models including p-tau217 (MAE=5.86, RMSE = 6.68), p-tau181 (MAE=6.86, RMSE=7.75), Aβ42/40 (MAE=7.88, RMSE=8.45), and PiB PET (MAE=6.81, RMSE=7.45)." (Results, Multiprotein models improve the prediction of EYO, clinical-converter paragraph) vs "The model containing only age, also exhibited inferior performance (MAE=7.57, RMSE=9.15)." (Results, Multiprotein models improve the prediction of EYO, clinical-converter paragraph). In converters, the multi-protein MAE exceeds age-only MAE by 7.88−7.57=0.31 years and p-tau217 MAE by 7.88−5.86=2.02 years, whereas its RMSE is 9.15−9.11=0.04 years lower than age-only RMSE. → Not supported by the paper's own data
  • These results suggest that mutation in these three genes drive changes that are similar regardless of the affected ADAD gene: "When PSEN1 carriers were compared to NC, the effect sizes of the two previously tested analyses were highly correlated (ρ=−0.86, p=3.20×10−39). Differences in p-values were most likely driven by differences in sample size. Similar results were observed when comparing PSEN2 (ρ=−0.09, p=0.34) or APP (ρ=−0.22, p=0.01) carriers to non-carriers (Figure 1D)." (Results, CSF proteome reveals widespread proteomic alterations, gene-stratified comparison) vs "These results suggest that mutation in these three genes drive changes that are similar regardless of the affected ADAD gene." (Results, CSF proteome reveals widespread proteomic alterations, gene-stratified comparison). The reported effect-size correlations are strongly inverse for PSEN1 (−0.86), near zero for PSEN2 (−0.09), and weakly inverse for APP (−0.22), rather than consistently strong correlations demonstrating similar changes across all three genes. → Not supported by the paper's own data
Reporting and transparencyNoted

The regression description does not distinguish linear from logistic modeling, the panel designation differs between the Abstract and Results, and the text does not quantify sample attrition during quality control.

Ethics approval: declared · Preregistration: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

60 of 60 checkable references verified

61 references in manuscript 1 have no canonical index record — counted, but not index-checkable 4 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The claim is supported by longitudinal CSF measurements from 484 participants across the international multi-site DIAN network, benchmarked against gold-standard assays and consistent with earlier published findings.

From the paper
“these proteins as potential early-stage biomarkers for disease detection, monitoring, and clinical benefits of targeting inflammation in symptomatic and presymptomatic individuals”

The paper names concrete real-world uses of its findings, namely disease detection, monitoring and clinical targeting of inflammation, but identifies no profession, organisation or service that would act on them.

Pathway

Clinicians and prevention-trial teams could use multiplex CSF protein signatures to stage presymptomatic Alzheimer's disease and time interventions.

Barrier

Evidence rests on a rare autosomal-dominant cohort; the panel lacks absolute quantification and validated clinical thresholds, and sporadic AD replication is needed.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →